Corient Private Wealth LP Buys Shares of 5,503 Medpace Holdings, Inc. $MEDP

Corient Private Wealth LP purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) during the 2nd quarter, Holdings Channel reports. The fund purchased 5,503 shares of the company’s stock, valued at approximately $2,914,000.

Other institutional investors and hedge funds have also modified their holdings of the company. BlackRock Inc. bought a new stake in shares of Medpace during the 2nd quarter valued at $1,323,047,000. AQR Capital Management LLC raised its holdings in Medpace by 65.1% in the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after purchasing an additional 404,226 shares during the period. Madison Asset Management LLC bought a new position in Medpace in the 2nd quarter worth $128,956,000. Bank of America Corp DE purchased a new position in Medpace during the second quarter valued at $116,891,000. Finally, Arrowstreet Capital Limited Partnership lifted its position in Medpace by 205.8% during the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock valued at $161,523,000 after purchasing an additional 211,411 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of MEDP stock opened at $583.21 on Wednesday. The stock has a fifty day simple moving average of $570.29 and a two-hundred day simple moving average of $496.46. The firm has a market capitalization of $16.28 billion, a PE ratio of 34.19, a PEG ratio of 2.65 and a beta of 1.15. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. The business had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business’s revenue was up 17.2% on a year-over-year basis. During the same period in the previous year, the business earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, sell-side analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on MEDP shares. Truist Financial boosted their price target on Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a report on Friday, July 24th. TD Cowen lifted their price objective on Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Jefferies Financial Group downgraded Medpace from a “buy” rating to a “hold” rating and boosted their price objective for the company from $490.00 to $515.00 in a research note on Tuesday, July 7th. Weiss Ratings raised shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. Finally, Leerink Partners set a $620.00 target price on shares of Medpace in a research note on Thursday, July 23rd. Three analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $584.18.

Insiders Place Their Bets

In other Medpace news, Director Brian T. Carley sold 5,000 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the completion of the sale, the director directly owned 27,825 shares of the company’s stock, valued at $16,935,129.75. This trade represents a 15.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Kevin M. Brady sold 3,400 shares of Medpace stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $625.24, for a total transaction of $2,125,816.00. Following the sale, the chief financial officer owned 12,830 shares in the company, valued at approximately $8,021,829.20. The trade was a 20.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 134,471 shares of company stock worth $82,151,311 over the last quarter. Company insiders own 20.50% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.